Sexual enhancement supplement recalled over three undeclared drugs
Parish SJ, Hahn SR. Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment.
| Issue | Description |
|---|---|
| Efficacy Debate | Some experts question the clinical significance of benefits |
| Side Effect Concerns | Risks of hypotension, syncope, and severe allergic reactions |
| Marketing & Approval Controversies | Criticism over FDA approval process and marketing practices |
| Post-Marketing Surveillance | Ongoing monitoring for rare adverse events |
The pharmacodynamic effects of combined administration of flibanserin and alcohol. Gao Z, Yang D, Yu L, Cui Y. Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis.
| Side Effect | Incidence | Recommendations |
|---|---|---|
| Hypotension | Rare | Monitor blood pressure |
| Syncope | Rare | Avoid alcohol and sedatives |
| Severe Allergic Reactions | Very rare | Immediate medical intervention |
Efficacy and safety of Flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. Systematic review and meta-analysis of Flibanserin’s effects and adverse events in women with hypoactive sexual desire disorder. Simon JA, Thorp J, Millheiser L.
I feel stressed due to my low desire
US FDA report on the approval of flibanserin 100 mg mentioned that, on average, treatment with flibanserin 100 mg increased the number of satisfying sexual events by 0.5 to one additional event per month over placebo. [27] The result of the present meta-analysis is within the range mentioned by the FDA for premenopausal women. The efficacy of 50 mg of flibanserin is far less in the same population. The drug has minimal efficacy in postmenopausal women and is not yet approved for treating HSDD in them. In addition, a mean of 1.71 eDiary sexual desire score was increased among the premenopausal women treated with flibanserin 100 mg; flibanserin at 50 mg daily doses was proven ineffective in this regard.
Incidence not known
Moreover, the FSFI desire domain score, which is extensively used as a measure of sexual desire in women, showed the superiority of flibanserin over placebo in both premenopausal (mean increase 0.30 for 100 mg and 0.25 for 50 mg) and postmenopausal women (0.25 for 100 mg). Similar trends were observed for the FSFI total score using flibanserin 100 mg in premenopausal and postmenopausal women. Flibanserin 100 mg also decreased the FSDS Item 13 score, the distress score related to sexual desire, by 0.3 premenopausal women and 0.2 postmenopausal women over placebo. Flibanserin (100 and 50 mg) also positively impacted FSDS-R total score reduction. The successful treatment of HSDD is directly associated with patient-reported outcomes (PGI-I and PBE) that capture women’s perspectives on improving their disease.
CNS Activity
Significantly more premenopausal women receiving flibanserin (both 100 mg and 50 mg) reported that their condition had improved (PGI-I). Similarly, more premenopausal and postmenopausal women reported a meaningful benefit from study medication (PBE) than those who received a placebo, suggesting that flibanserin provides a meaningful benefit to women with HSDD. The clinical efficacy of flibanserin 100 mg in improving FSFI-d and total scores, FSDS-R item 13 and total scores, and positive responders during PBE was better in premenopausal women than in postmenopausal women. Flibanserin use was associated with higher risks of AEs and drug-related AEs, although these were of mild to moderate intensity. Serious AEs and severe AEs were equally low in flibanserin and placebo groups, although more study subjects taking flibanserin discontinued the study due to AEs. Flibanserin for premenopausal hypoactive sexual desire disorder: pooled analysis of clinical trials. Simon JA, Clayton AH, Kim NN, Patel S. Clinically meaningful benefit in women with hypoactive sexual desire disorder treated with Flibanserin.
- Flibanserin was developed by Boehringer Ingelheim, later licensed to Sprout Pharmaceuticals.
- It is considered a "female Viagra," though its mechanism differs from male erectile drugs.
- The medication is part of the growing field of female sexual dysfunction treatment.
- Most clinical trials showed a modest increase in satisfying sexual events.
- Flibanserin should be taken consistently for best results.
- It is not recommended for women who are pregnant or breastfeeding.
- Common adverse reactions include dry mouth and insomnia.
- The drug was approved after extensive clinical trials involving thousands of women.
- Long-term safety data is still being collected.
Kamrul-Hasan A, Alam MS, Talukder SK, Dutta D, Selim S. Efficacy and safety of omarigliptin, a novel once-weekly dipeptidyl peptidase-4 inhibitor, in type 2 diabetes mellitus: a systematic review and meta-analysis.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 50mg | 60 + 4 Pills | 83.93€ 79.93€ | |
| Viagra Professional | 100mg | 360 + 6 Pills | 527.09€ 501.99€ | |
| Kamagra Gold | 50 mg | 84 + 6 Pills | 224.77€ 214.07€ | |
| Levitra Generic | 10mg | 270 + 10 Pills | 338.09€ 321.99€ | |
| Levitra Generic | 60mg | 90 + 6 Pills | 291.82€ 277.92€ | |
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Levitra Original | 20mg | 4 Pills | 45.87€ 43.69€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Viagra Generic | 50mg | 30 + 4 Pills | 54.26€ 51.68€ | |
| Kamagra 100 mg | 100 mg | 60 + 4 Pills | 201.34€ 191.75€ | |
| Kamagra Oral Jelly | 100mg | 63 + 7 Sachets | 224.18€ 213.50€ | |
| Viagra Generic | 50mg | 20 Pills | 40.52€ 38.59€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Kamagra Soft Tabs | 100mg | 120 + 6 Pills | 311.78€ 296.93€ | |
| Viagra Generic | 25mg | 120 + 6 Pills | 125.56€ 119.58€ |
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.
Addyi is the #1 Prescribed Treatment for HSDD.1
The risks of somnolence (RR 4.04) and dizziness (RR 3.95) were highest among the AEs with 100 and vardenafil 5 mg 50 mg doses. Risks for fatigue, nausea, and insomnia were increased by flibanserin 100 mg but not flibanserin 50 mg. In an open-label extension study after RCTs of flibanserin, 1.2% of participants reported serious AEs over 52 weeks of follow-up, and 10.7% of participants discontinued treatment due to AEs. Additionally, 15.8%, 1.6%, 7.6%, 6.9%, 6.3%, and 1.4% of participants reported somnolence, sedation, fatigue, dizziness, nausea, and vomiting, respectively. [26] Moreover, severe AEs included hypotension and syncope, which are amplified with concurrent alcohol intake.
Related treatment guides
[28] Appropriate patient selection, avoidance of concomitant alcohol and other drugs that might increase the risks of flibanserin-associated AEs, and taking the drug at bedtime may reduce the AEs. The advisory committee of the US FDA acknowledged the small treatment effects and substantial safety concerns but considered the unmet medical need while recommending FDA approval of flibanserin. Alongside, issues related to drug-drug interactions, consideration of nonpharmacologic approaches to HSDD with less importance, concerns about “medicalizing” low sexual desire, and the change from HSDD to FSIAD are drawing attention to the regulatory authorities for continuing the approval status of the drug. The main strength of this meta-analysis is the inclusion of a large population from a fairly good number of studies. The general quality of the included trials was good; all were phase 3 RCTs and double-blind trials.
Contact Us
The certainty of the evidence generated is moderate to high for primary outcomes. We have separately analyzed the efficacy outcomes comparing flibanserin 100 and 50 mg with the placebo in pre- and postmenopausal women. Moreover, sub-analyses of safety outcomes compared flibanserin 100 and 50 mg with the placebo; such reports are missing in the previous meta-analyses. Furthermore, the meta-analysis included results of all RCTs available to date. Only fildena professional 100 2 studies were conducted among postmenopausal women. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
What is Addyi (flibanserin)?
In one study, there was a 24-week open-label period before the double-blind period, which might have reduced drug response. in another study[21] were included in the flibanserin 50 and 100 mg arms, respectively. dosing might have different efficacy and adverse effect potentials than the once-daily nighttime dosing. The certainty of the evidence generated was very low for any AEs and low for dizziness and fatigue. In this meta-analysis, flibanserin showed modest benefits in treating HSDD, with the cost of higher AE risks, although the AEs were mild in nature.
Storage Class
Premenopausal women with HSDD were more benefited than premenopausal women with the condition. The higher dose (flibanserin 100 mg) was more effective in treating HSDD but imparted higher risks of AEs. The continued efficacy and safety of flibanserin for long-term use still remain to be established. Grades of Recommendation, Assessment, Development, and Evaluation Preferred Reporting Items for Systematic Reviews and Meta-Analyses McCabe MP, Sharlip ID, Atalla E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial.
- Flibanserin's mechanism involves increasing dopamine and norepinephrine and decreasing serotonin levels.
- It does not address libido caused by relationship issues or physical health problems.
- Flibanserin was once controversial due to debates over its effectiveness.
- It is not suitable for women taking certain antidepressants due to drug interactions.
- The medication has warnings for severe hypotension and syncope.
- Patients are advised to avoid alcohol consumption completely while on the drug.
- Flibanserin's approval was considered a breakthrough for female sexual health.
- Insurance coverage for flibanserin varies and can be limited.
- The drug's marketing emphasizes the importance of patient counseling.
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. female sexual dysfunction; female sexual interest/arousal disorder; flibanserin; hypoactive sexual desire disorder; meta-analysis; satisfying sexual events
What SIDE EFFECTS can this medicine cause?
Compared to the placebo group, a similar number of subjects in the flibanserin 100 mg and flibanserin 50 mg groups experienced headache. Fatigue (RR 1.91, 95% CI [1.30, 2.81], P = .01, I2 = 53% [moderate heterogeneity], low certainty of evidence), nausea (RR 2.37, 95% CI [1.69, 3.33], P < .000001, I2 = 54% [moderate heterogeneity], moderate certainty of evidence), somnolence (RR 4.04, 95% CI [3.15, 5.18], P < .000001, I2 = 0% [not important heterogeneity], moderate certainty of evidence), and insomnia (RR 1.69, 95% CI [1.09, 2.62], P = .02, I2 = 0% [not important heterogeneity], moderate certainty of evidence) were more frequent in the flibanserin 100 mg group than in the placebo group. Subjects in the flibanserin 50 mg group also exhibited a higher risk of somnolence than the placebo group (RR 2.08, 95% CI [1.30, 3.35], P = .002, I2 = 34% [mild heterogeneity]). The present meta-analysis incorporated the results of RCTs of flibanserin in HSDD that are available to date. It highlights the efficacy and adverse events of flibanserin compared to a placebo used to manage HSDD in pre-and postmenopausal women.
A note about sex and gender
Flibanserin is more effective than placebo in treating HSDD, although its use is associated with higher risks of AEs. US FDA approved flibanserin in August 2015 as the first medication to treat acquired, generalized HSDD in premenopausal women. [27] Flibanserin is a non-hormonal oral medicine that acts on the brain to increase sexual desire. The mechanism by which flibanserin improves sexual desire and related distress is not known; this may be attributed to its high affinity for 5-HT1A and 5-HT2A receptors, displaying agonist activity on 5-HT1A and antagonist on 5-HT2A, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Serotonin exerts an inhibitory influence on sexual activity by reducing dopamine release in the prefrontal cerebral cortex.
Interactions with Medicines
Both dopamine and norepinephrine are essential components in the process of sexual excitation. Norepinephrine serves as a stimulant in sexual arousal, while dopamine contributes to the enhancement of desire. By modulating these monoamines in patients with HSDD, flibanserin improves sexual desire and arousal. In premenopausal women, flibanserin use was associated with 0.69 and 0.32 additional SSE per month at 100 and 50 mg daily doses; the number was 0.37 in postmenopausal women with flibanserin 100 mg. The improvement is not as robust as expected.